Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 5 mechanisms across 20 industry trials with a known mechanism of action.

See full pipeline →

Melatonin Receptor Agonist

7 trials 2 active 3 sponsors

Orexin Receptor Antagonist

8 trials 1 active 2 sponsors

GABA receptor

3 trials 2 sponsors

alpha 2 -delta site

1 trials 1 sponsor

Benzodiazepine Antagonist

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

124 industry-sponsored trials across 57 sponsors

View full landscape →

Showing 11 of 11 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
ProofPilot	—	—	ACTIVE NOT RECRUITING	2021-01-31	NCT04627480
Pharmanovia	Chloral Hydrate	—	COMPLETED	2024-04-24	NCT06053840
Idorsia Pharmaceuticals Ltd.	Daridorexant	—	COMPLETED	2024-04-12	NCT05597020
Max Zeller Soehne AG	Valerian-Hop Extract	—	COMPLETED	2023-12-20	NCT05684523
Takeda	Ramelteon	Melatonin Receptor Agonist [EPC]	COMPLETED	2018-01-31	NCT02669082
ResMed	—	—	COMPLETED	2015-04	NCT01164592
EMS	Zolpidem Hemitartrate	—	COMPLETED	2013-11-11	NCT01896336
Astellas Pharma Inc	Zolpidem MR	—	COMPLETED	2011-04	NCT01181232
Sanofi	ZOLPIDEM	—	COMPLETED	2011-04	NCT01097382
Astellas Pharma Inc	Zolpidem MR	—	COMPLETED	2010-11	NCT00956319
Sanofi	ZOLPIDEM SL800750	—	COMPLETED	2010-07	NCT01024192

Showing 42 of 42 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Vanda Pharmaceuticals	Tasimelteon	Melatonin Receptor Agonist [EPC]	RECRUITING	2026-06	NCT04652882
Merck	Suvorexant	Orexin Receptor Antagonist [EPC]	RECRUITING	2027-06-24	NCT06655883
Vanda Pharmaceuticals	Tasimelteon Oral Suspension	—	RECRUITING	2027-11	NCT06953869
Avecho Biotechnology	Cannabidiol (CBD) Capsule 75mg	—	RECRUITING	2025-12	NCT05840822
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.	YZJ-1139	—	RECRUITING	2025-08	NCT06975514
Vanda Pharmaceuticals	Tasimelteon	Melatonin Receptor Agonist [EPC]	RECRUITING	2025-06-30	NCT06701396
Nanjing Chia-tai Tianqing Pharmaceutical	Ramelteon	Melatonin Receptor Agonist [EPC]	NOT YET RECRUITING	2026-12	NCT06512363
Jiangsu Hansoh Pharmaceutical Co., Ltd.	HS-10506	—	NOT YET RECRUITING	2028-06-28	NCT07587385
Nxera Pharma Korea Co., Ltd.	Daridorexant	—	COMPLETED	2025-09-23	NCT07028697
Jiangsu Simcere Pharmaceutical Co., Ltd.	Daridorexant	—	COMPLETED	2024-04-12	NCT06010693
Taisho Pharmaceutical Co., Ltd.	TS-142 5 mg	—	COMPLETED	2024-03-07	NCT05461352
Avadel	FT218	—	COMPLETED	2023-12-22	NCT04451668
Taisho Pharmaceutical Co., Ltd.	TS-142 5 mg	—	COMPLETED	2023-12-05	NCT05453136
Idorsia Pharmaceuticals Ltd.	Daridorexant 10 mg	—	COMPLETED	2021-02-22	NCT03679884
Idorsia Pharmaceuticals Ltd.	Daridorexant	—	COMPLETED	2020-04-09	NCT03575104
Eisai Inc.	LEM 5 mg	—	COMPLETED	2020-03-17	NCT04009577
Idorsia Pharmaceuticals Ltd.	Daridorexant 25 mg	—	COMPLETED	2020-01-25	NCT03545191
Eisai Inc.	lemborexant	Orexin Receptor Antagonist [EPC]	COMPLETED	2019-01-08	NCT02952820
Nobelpharma	NPC-15 Granules Lower Dose	—	COMPLETED	2018-09	NCT02757066
Nobelpharma	NPC-15	—	COMPLETED	2018-07	NCT02757079
Neurim Pharmaceuticals Ltd.	Circadin 2/5/10 mg	—	COMPLETED	2018-03-27	NCT01906866
Sequential Medicine Ltd	SM-1	—	COMPLETED	2018-03-20	NCT03331042
Vanda Pharmaceuticals	Tasimelteon	Melatonin Receptor Agonist [EPC]	COMPLETED	2018-03-05	NCT03373201
Eisai Inc.	Lemborexant	Orexin Receptor Antagonist [EPC]	COMPLETED	2018-01-30	NCT02783729
Eurofarma Laboratorios S.A.	Eszopiclone	GABA receptor	COMPLETED	2012-03	NCT01100164
Merck	Suvorexant High Dose (HD)	—	COMPLETED	2011-11-08	NCT01097629
Sumitomo Pharma America, Inc.	eszopiclone	GABA receptor	COMPLETED	2011-10	NCT00857220
Merck	Suvorexant High Dose (HD)	—	COMPLETED	2011-09-09	NCT01097616
Sumitomo Pharma America, Inc.	eszopiclone	GABA receptor	COMPLETED	2011-07	NCT00856973
Merck	Suvorexant	Orexin Receptor Antagonist [EPC]	COMPLETED	2011-05-17	NCT01021813
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Pregabalin	alpha 2 -delta site	COMPLETED	2010-06	NCT00883740
Eisai Co., Ltd.	Eszopiclone 1 mg	—	COMPLETED	2010-05	NCT00770510
Eisai Co., Ltd.	Eszopiclone 1 mg- Elderly	—	COMPLETED	2010-05	NCT00770692
Merck	Esmirtazapine	—	COMPLETED	2010-02-14	NCT00561574
Merck	Esmirtazapine	—	COMPLETED	2009-11-19	NCT00631657
Midnight Pharma, LLC	almorexant	—	COMPLETED	2009-09	NCT00608985
Sanofi	Eplivanserin	—	COMPLETED	2009-06	NCT00805350
Targeted Medical Pharma	Trazodone	—	COMPLETED	2008-10	NCT01468038
Biogen	SAGE-217	—	TERMINATED	2019-12-20	NCT03771664
Merck	esmirtazapine	—	TERMINATED	2010-03-10	NCT00750919
Sequential Medicine Ltd	SM-1	—	WITHDRAWN	2023-12	NCT03338764
9305-9954 Quebec Inc	CALPXT96	—	WITHDRAWN	2016-12	NCT02232256

Showing 39 of 39 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Reconnect Labs	RE03	—	RECRUITING	2026-08-01	NCT06685965
RDC Clinical Pty Ltd	—	—	RECRUITING	2027-02	NCT07315516
Proactive Life Inc	—	—	NOT YET RECRUITING	2026-12-30	NCT07316153
Afasci Inc	AFA-281	—	NOT YET RECRUITING	2027-06-01	NCT06710431
Apsen Farmaceutica S.A.	APSTZD 1	—	NOT YET RECRUITING	2027-09-23	NCT07420816
Sequential Medicine Ltd	SM-1	—	NOT YET RECRUITING	2020-06-30	NCT04396327
Biologische Heilmittel Heel GmbH	Neurexan	—	COMPLETED	2026-01-31	NCT06278077
Idorsia Pharmaceuticals Ltd.	Daridorexant 10 mg	—	COMPLETED	2026-01-12	NCT05423717
Orion Corporation, Orion Pharma	Tasipimidine	—	COMPLETED	2025-09-11	NCT06956495
Bod Australia	50 mg Cannabidiol (CBD)	—	COMPLETED	2023-07-07	NCT05253417
Defined Research	Defined CBD	—	COMPLETED	2022-07-02	NCT05233761
Taisho Pharmaceutical Co., Ltd.	TS-142	—	COMPLETED	2021-11-16	NCT04469023
Imbrium Therapeutics	V117957 tablets	—	COMPLETED	2020-11-06	NCT04035200
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.	YZJ-1139 10mg	—	COMPLETED	2020-09-30	NCT06680505
Johnson & Johnson	JNJ-42847922, 5 mg	—	COMPLETED	2019-04-03	NCT03375203
Taisho Pharmaceutical Co., Ltd.	TS-142	—	COMPLETED	2019-02-13	NCT04573725
Idorsia Pharmaceuticals Ltd.	ACT-541468	—	COMPLETED	2017-05-31	NCT02841709
Idorsia Pharmaceuticals Ltd.	Zolpidem	—	COMPLETED	2017-04-21	NCT03056053
Idorsia Pharmaceuticals Ltd.	ACT-541468 5 mg	—	COMPLETED	2017-04-12	NCT02839200
Sequential Medicine Ltd	SM-1	—	COMPLETED	2016-06	NCT02671760
Johnson & Johnson	JNJ-42847922	—	COMPLETED	2015-12-02	NCT02464046
Respicardia, Inc.	—	—	COMPLETED	2014-08	NCT01124370
Eisai Inc.	E2006	—	COMPLETED	2014-04-29	NCT01995838
Neurim Pharmaceuticals Ltd.	Circadin	—	COMPLETED	2013-02	NCT00940589
Neurim Pharmaceuticals Ltd.	Neu-P11	—	COMPLETED	2012-05	NCT01489969
Intec Pharma Ltd.	Zaleplon AP formulation	—	COMPLETED	2011-09	NCT01277107
Merck	MK-6096	—	COMPLETED	2011-02-01	NCT01021852
Somnus Therapeutics, Inc.	SKP-1041 (experimental formulation of zaleplon)	—	COMPLETED	2010-12	NCT00878553
GSK	—	—	COMPLETED	2010-08-10	NCT03105297
GSK	—	—	COMPLETED	2010-02-01	NCT01122849
Eli Lilly	LY2624803	—	COMPLETED	2010-02	NCT00784875
Merck	Suvorexant	Orexin Receptor Antagonist [EPC]	COMPLETED	2009-12-26	NCT00792298
GSK	GW597599	—	COMPLETED	2009-09	NCT00992160
Arena Pharmaceuticals	APD125	—	COMPLETED	2008-10	NCT00664664
Intec Pharma Ltd.	IN 10 003 formulation A	—	COMPLETED	—	NCT01196650
Canopy Growth Corporation	CHI-921	—	TERMINATED	2020-06-17	NCT03984604
Neurogen Corporation	Adipiplon	—	TERMINATED	2008-10	NCT00683436
EMS	Hipnos 3	—	WITHDRAWN	2022-02	NCT03814135
Pfizer	PD 0200390	—	WITHDRAWN	2009-06	NCT00748592

Showing 32 of 32 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.	YZJ-1139	—	ACTIVE NOT RECRUITING	2024-11-10	NCT06671444
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.	YZJ-1139 tablets	—	ACTIVE NOT RECRUITING	2024-09-18	NCT06680531
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.	YZJ-1139 tablets	—	ACTIVE NOT RECRUITING	2024-09-13	NCT06671470
Nyree Penn	Diprivan (propofol), Astra-Zeneca	—	NOT YET RECRUITING	2026-05-01	NCT06644573
Overseas Pharmaceuticals, Ltd.	Test product (T): Ramelteon Modified-Release Tablets	—	COMPLETED	2024-07-02	NCT06890715
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.	YZJ-1139	—	COMPLETED	2024-04-18	NCT06671509
Sunshine Lake Pharma Co., Ltd.	HEC83518	—	COMPLETED	2021-07-09	NCT04667429
Sunshine Lake Pharma Co., Ltd.	HEC83518 tablets	—	COMPLETED	2020-09-10	NCT04596007
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.	YZJ-1139	—	COMPLETED	2019-04-10	NCT06685341
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.	YZJ-1139	—	COMPLETED	2018-11-21	NCT06673927
Eisai Inc.	Zolpidem tablets	—	COMPLETED	2018-07-04	NCT03158025
Vanda Pharmaceuticals	tasimelteon	Melatonin Receptor Agonist [EPC]	COMPLETED	2017-12-20	NCT02776215
Eisai Inc.	Lemborexant 5 mg	—	COMPLETED	2015-04-21	NCT02350309
Eisai Inc.	E2006	—	COMPLETED	2012-10	NCT01673880
Eisai Inc.	E2006 1.0 mg	—	COMPLETED	2012-08-11	NCT01463098
Merck	suvorexant	Orexin Receptor Antagonist [EPC]	COMPLETED	2012-01-20	NCT01293006
Merck	MK-4305 40 mg	—	COMPLETED	2011-11	NCT01311882
Merck	—	—	COMPLETED	2011-09-01	NCT01209728
Abbott	ABT-652	—	COMPLETED	2011-04	NCT01124851
Takeda	Ramelteon	Melatonin Receptor Agonist [EPC]	COMPLETED	2011-03	NCT00914862
Neurim Pharmaceuticals Ltd.	Neu-P11	—	COMPLETED	2011-02	NCT01114126
Coeruleus Ltd.	Flumazenil	Benzodiazepine Antagonist [EPC]	COMPLETED	2010-12	NCT01655914
Eli Lilly	LY2624803	—	COMPLETED	2010-12	NCT01236105
Transcept Pharmaceuticals	zopiclone	—	COMPLETED	2010-09	NCT01106859
Merck	Suvorexant	Orexin Receptor Antagonist [EPC]	COMPLETED	2010-07-15	NCT01059851
Merck	Suvorexant	Orexin Receptor Antagonist [EPC]	COMPLETED	2010-04-14	NCT01043926
GSK	Atorvastatin	—	COMPLETED	2010-02-26	NCT01299597
Eisai Co., Ltd.	Eszopiclone 3 mg	—	COMPLETED	2010-02	NCT01055834
GSK	SB-649868	—	COMPLETED	2010-01-06	NCT01030939
Eli Lilly	LY2624803 - Capsules	—	COMPLETED	2008-11	NCT01779830
Pfizer	PD 0200390	—	COMPLETED	2008-05	NCT00722306
Eli Lilly	LY2624803	—	TERMINATED	2010-11	NCT01257178

Novel Drugs by Company (New molecular entities)

EISAI INC 1 drug

IDORSIA 1 drug

DARIDOREXANT HYDROCHLORIDE

NDA 2022

Reformulations (9 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.